Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation
Xue Gong, … , Gengze Wu, Chunyu Zeng
Xue Gong, … , Gengze Wu, Chunyu Zeng
Published December 15, 2021
Citation Information: J Clin Invest. 2021;131(24):e147031. https://doi.org/10.1172/JCI147031.
View: Text | PDF
Research Article Cardiology Vascular biology

Circular RNA circEsyt2 regulates vascular smooth muscle cell remodeling via splicing regulation

  • Text
  • PDF
Abstract

Circular RNAs (circRNAs) have been recently recognized as playing a role in the pathogenesis of vascular remodeling–related diseases by modulating the functions of miRNAs. However, the interplay between circRNAs and proteins during vascular remodeling remains poorly understood. Here, we investigated a previously identified circRNA, circEsyt2, whose expression is known to be upregulated during vascular remodeling. Loss- and gain-of‑function mutation analyses in vascular smooth muscle cells (VSMCs) revealed that circEsyt2 enhanced cell proliferation and migration and inhibited apoptosis and differentiation. Furthermore, the silencing of circEsyt2 in vivo reduced neointima formation, while circEsyt2 overexpression enhanced neointimal hyperplasia in the injured carotid artery, confirming its role in vascular remodeling. Using unbiased protein–RNA screening and molecular validation, circEsyt2 was found to directly interact with polyC-binding protein 1 (PCBP1), an RNA splicing factor, and regulate PCBP1 intracellular localization. Additionally, circEsyt2 silencing substantially enhanced p53β splicing via the PCBP1–U2AF65 interaction, leading to the altered expression of p53 target genes (cyclin D1, p21, PUMA, and NOXA) and the decreased proliferation of VSMCs. Thus, we identified a potentially novel circRNA that regulated vascular remodeling, via altered RNA splicing, in atherosclerotic mouse models.

Authors

Xue Gong, Miao Tian, Nian Cao, Peili Yang, Zaicheng Xu, Shuo Zheng, Qiao Liao, Caiyu Chen, Cindy Zeng, Pedro A. Jose, Da-Zhi Wang, Zhao Jian, Yingbin Xiao, Ding-Sheng Jiang, Xiang Wei, Bing Zhang, Yibin Wang, Ken Chen, Gengze Wu, Chunyu Zeng

×

Figure 7

CircEsyt2 inhibits the nuclear trafficking of PCBP1 by binding directly to PCBP1.

Options: View larger image (or click on image) Download as PowerPoint
CircEsyt2 inhibits the nuclear trafficking of PCBP1 by binding directly ...
(A) Western blotting of proteins pulled down by control and circEsyt2 probes in circEsyt2-OE HEK293T cells using the PCBP1 antibody. (B) Identification of circEsyt2-binding proteins. Left: silver staining of pulled-down proteins in circEsyt2-OE HEK293T cells. Right: mass spectrometry showing the main proteins pulled down by the circEsyt2 probe. (C) RIP-qPCR assay confirming the direct binding of PCBP1 to circEsyt2 in HASMCs. ***P < 0.001 vs. IgG. n = 3. (D) RIP-qPCR assay detecting the specific binding of PCBP1 and circEsyt2 in HASMCs by circEsyt2 silencing. Scrambled siRNA (scr) served as control. *P < 0.05 vs. scr. n = 3. (E) FISH of circEsyt2 (red), PCBP1 (green), and DAPI (blue) in HASMCs transfected with circEsyt2 plasmid. Scale bars: 20 μm. (F) Coimmunofluorescence of PCBP1 (red), α-SMA (green), and DAPI (blue) in circEsyt2-silenced HASMCs. Scale bars: 50 μm. (G) Western blotting to check the expression of cytoplasmic (C) and nuclear (N) PCBP1, treated as in F. Cytoplasmic control: GAPDH; nuclear control: histone 3 (H3). *P < 0.05, **P < 0.01 vs. scr. n = 3. (H) Coimmunofluorescence staining for PCBP1 (red), α-SMA (green), and DAPI (blue) in injured carotid arteries of the control (sh-con) and circEsyt2 knockdown (sh-circ) groups. Scale bars: 50 μm (bright field) and 20 μm (immunofluorescence). (I) Western blotting to check the expression of cytoplasmic and nuclear PCBP1 in carotid arteries, treated as in H. *P < 0.05, **P < 0.01 vs. sh-con. n = 3. Data are mean ± SEM. Two-sided unpaired t test for C, D, G, and I.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts